S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan

Insmed (INSM) Stock Price, News & Analysis

$28.06
+0.34 (+1.23%)
(As of 03/1/2024 ET)
Today's Range
$27.89
$28.65
50-Day Range
$26.60
$31.74
52-Week Range
$16.04
$32.00
Volume
2.04 million shs
Average Volume
1.65 million shs
Market Capitalization
$4.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.10

Insmed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.7% Upside
$45.10 Price Target
Short Interest
Healthy
6.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
0.44mentions of Insmed in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$4.15 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.63) to ($3.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.18 out of 5 stars

Medical Sector

168th out of 950 stocks

Pharmaceutical Preparations Industry

69th out of 418 stocks


INSM stock logo

About Insmed Stock (NASDAQ:INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

INSM Stock Price History

INSM Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Insmed To Present at Three March Conferences
Insmed (NASDAQ:INSM) PT Raised to $54.00 at Guggenheim
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Insmed (NASDAQ:INSM) Research Coverage Started at UBS Group
Insmed (NASDAQ:INSM) Upgraded by StockNews.com to Hold
Insmed Full Year 2023 Earnings: EPS Misses Expectations
Insmed: Q4 Earnings Snapshot
Insmed Posts Wider Loss In Q4 - Quick Facts
What Wall Street expects from Insmed's earnings
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/03/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.10
High Stock Price Target
$55.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+60.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-749,570,000.00
Net Margins
-245.59%
Pretax Margin
-244.76%

Debt

Sales & Book Value

Annual Sales
$305.21 million
Book Value
($2.24) per share

Miscellaneous

Free Float
142,107,000
Market Cap
$4.17 billion
Optionable
Optionable
Beta
0.92

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report














INSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price target for 2024?

10 brokers have issued 12-month price objectives for Insmed's shares. Their INSM share price targets range from $36.00 to $55.00. On average, they predict the company's stock price to reach $45.10 in the next twelve months. This suggests a possible upside of 60.7% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2024?

Insmed's stock was trading at $30.99 at the beginning of 2024. Since then, INSM stock has decreased by 9.5% and is now trading at $28.06.
View the best growth stocks for 2024 here
.

Are investors shorting Insmed?

Insmed saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 9,230,000 shares, a decline of 11.2% from the January 31st total of 10,390,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the short-interest ratio is presently 5.4 days.
View Insmed's Short Interest
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.15. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. The business's revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.20) earnings per share.

What guidance has Insmed issued on next quarter's earnings?

Insmed issued an update on its FY 2024 earnings guidance on Saturday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $359.5 million.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Who are Insmed's major shareholders?

Insmed's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.87%), Price T Rowe Associates Inc. MD (7.52%), Palo Alto Investors LP (3.85%), Bellevue Group AG (1.60%), Norges Bank (1.02%) and Northern Trust Corp (0.96%). Insiders that own company stock include David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INSM) was last updated on 3/3/2024 by MarketBeat.com Staff